E-selectin antagonist compounds for metastasis and thrombosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer and thrombosis are limited in effectiveness, particularly in preventing metastasis and venous thromboembolism, as they often lead to endothelial injury and have nonspecific diagnostic symptoms, resulting in high mortality rates and complications.
Innovation Solution
Development of glycomimetic compounds that act as E-selectin antagonists, inhibiting the binding of E-selectin to its ligands, which are used in pharmaceutical compositions to treat and prevent metastasis, thrombosis, and enhance hematopoietic stem cell survival, either alone or in combination with chemotherapy and radiotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for cancer and thrombosis are used, then treatment options are available, but effectiveness is limited and endothelial injury occurs
Solution Approach 1:
The patent uses E-selectin as a mediator/target to block the harmful interaction between leukocytes and endothelial cells. By administering E-selectin antagonists (small molecules, antibodies, or aptamers), the treatment prevents leukocyte adhesion to endothelium without directly damaging the endothelial cells, thus resolving the contradiction between treatment effectiveness and avoidance of endothelial injury
Solution Approach 2:
The patent converts the harmful E-selectin-mediated adhesion process into a beneficial therapeutic target. By blocking E-selectin, the treatment prevents pathological leukocyte recruitment that causes tissue damage in conditions like cancer metastasis and thrombosis, while preserving normal physiological functions
2Measurement precision
If current treatments are used, then diagnostic symptoms are obtained, but symptoms are nonspecific resulting in high mortality rates
Solution Approach 1:
The patent employs detectable labels (fluorophores, radiolabels, enzymatic labels) attached to E-selectin antagonists or associated molecules, enabling specific visualization and detection of E-selectin expression and leukocyte adhesion events. This provides highly specific diagnostic signals that can distinguish pathological processes from normal physiology, improving diagnostic precision and enabling early intervention before mortality increases
3Reliability
If E-selectin antagonists are used, then metastasis and thrombosis are inhibited, but stability and bioavailability must be improved
Solution Approach 1:
The patent employs multiple types of E-selectin antagonists with different structural characteristics (small molecules, monoclonal antibodies, aptamers) to achieve both high inhibition effectiveness and improved stability. Each class offers different stability and bioavailability profiles, allowing selection or combination based on specific therapeutic needs
Solution Approach 2:
The patent modifies molecular parameters of E-selectin antagonists (chemical structure, glycosylation patterns, PEGylation) to enhance stability and bioavailability while maintaining inhibitory activity. These parameter changes allow optimization of pharmacokinetic properties without sacrificing therapeutic effectiveness
Data Source
AI summary
Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand. Described herein are E-selectin antagonists including, for example, glycomimetic compounds, antibodies, aptamers and peptides that are useful in methods for treatment of cancers, and treatment and prevention of metastasis, inhibiting infiltration of the cancer cells into bone marrow, reducing or inhibiting adhesion of the cancer cells to endothelial cells including cells in bone marrow, and inhibiting thrombus formation.